A digital service is now being offered to people who are concerned they may have exposed to a sexually transmitted disease but are afraid to go to a clinic.
It appears that digital service option is growing in popularity, which is being tested in London. According to a report of the online-based STD testing, there has been a significant rise in the service for a number of boroughs in South London.
It’s the first United Kingdom study to look at access in Internet testing versus conventional testing.
According to a study from the London School of Hygiene and Tropical Medicine, offering the STD digital testing services means more people getting tested for HIV, syphilis, gonorrhea and chlamydia. It would certainly be beneficial to people in the high-risk groups.
Over 30 kinds of bacteria, parasites and viruses are transmittable through sexual activity. While some diseases display symptoms, others do not. In 2015, the figures showed that 1.1 billion had an STD other than HIV.
New healthy policy strategies, such as the method to go digital, are needed to address the risk of STDs. According to a new study, testing increased was nearly doubled in a group that uses e-STI testing compared to a group invited to use only health clinics existing services. The participants were permitted to choose any service or intervention during this time.
With the Internet service, people were sent home test kits, sending those kits back. The results were mailed back to them how they choose – email, post or text.
Dr. Emma Wilson is the lead researcher for the e-STI testing service, and she said it was being implemented throughout the UK to ensure the rise in STD testing demand was met. Wilson said the study looked at how effective e-STI testing was for common STDs.
Here’s what we've been up to recently.
Several recent studies have backed up a claim that herpes infections can cause cognitive diseases like Alzheimer’s. There is so much research about it that researchers said it would be safe to assume that the virus could be a cause for Alzheimer’s and other cognitive diseases.
The World Health Organization (WHO) is using new evidence about the HIV drug dolutegravir (DTG) to suggest it be the first and second line of treatment for populations such as pregnant women and women of childbearing ages.